Pergolide treatment of ocular chemical injury

Patent metadata

Field	Value
Publication number	US-2024325378-A1
Application number	US-202418622144-A
Country	US
Kind code	A1
Filing date	Mar 29, 2024
Priority date	Mar 31, 2023
Publication date	Oct 3, 2024
Grant date	—

Abstract

Chemical injuries to the eye can cause permanent vision impairment or blindness, as well as chronic pain and dry eye syndrome. Disclosed herein is a method of treating an ocular chemical burn by administering an effective amount of pergolide to an eye of a subject, such as via a topical formulation. Further disclosed are compositions and kits used for that treatment, such as pergolide solutions, and pergolide eye drop formulations.

First claim

We claim:

1 . A method of treating an ocular chemical burn, comprising administering an effective amount of pergolide to an eye of a subject having the ocular chemical burn.

2 . The method of claim 1 , further comprising selecting the subject having the ocular chemical burn.

3 . The method of claim 1 , wherein the pergolide is administered as a pergolide solution via eye drop.

4 . The method of claim 3 , wherein the effective amount of the pergolide solution administered is a drop of about 25 μl to about 60 μl;
about 5 μl to about 7 μl on the cornea; or
about 7 μl to about 10 μl on the eyelid fornix.

5 . The method of claim 4 , wherein the concentration of pergolide in the pergolide solution is about 50 μg/ml to about 600 μg/ml.

6 . The method of claim 5 , wherein the concentration of pergolide in the pergolide solution is about 300 μg/ml.

7 . The method of claim 5 , wherein the concentration of pergolide in the pergolide solution is about 600 μg/ml.

8 . The method of claim 3 , wherein administering the effective amount of the pergolide solution does not result in cardiac valvulopathy in the subject.

9 . The method of claim 8 , wherein administering the effective amount of the pergolide solution does not result in valvular fibrosis, significant cardiac glycosaminoglycan deposits, or cardiac myxoid changes in the subject.

10 . The method of claim 3 , wherein the eye drop is administered 3 times a day, 2 times a day, or 1 time a day.

11 . The method of claim 1 , wherein the ocular chemical burn is caused by an alkali compound.

12 . The method of claim 1 , wherein administering the effective amount of pergolide reduces corneal haze.

13 . The method of claim 1 , wherein administering the effective amount of pergolide increases central corneal nerve fiber density.

14 . The method of claim 13 , wherein the central corneal nerve fiber density is increased within 3 weeks following the administering.

15 . The method of claim 1 , wherein administering the effective amount of pergolide prevents a decrease in limbal nerve density.

16 . The method of claim 15 , wherein the limbal nerve density is increased within 3 weeks following the administering compared to a control.

17 . The method of claim 1 , wherein the subject did not previously receive ocular nerve grafting.

18 . The method of claim 1 , further comprising administering an effective amount of a cycloplegic, a NSAID, a steroid, vitamin C, an antibiotic, lubricating eye drops, doxycycline, a tetracycline derivative, a non-aminoglycoside ocular antibiotic, erythromycin, a fluoroquinolone, mitomycin C, a medroxprogesterone eyedrop, a amniotic membrane eyedrop, an autologous/allogenic eye drop, a citrate eye drop, or an ascorbate eye drop to the eye of the subject having the ocular chemical burn.

19 . The method of claim 3 , wherein the pergolide solution comprises hyaluronate or hydroxypropyl methylcellulose.

20 . A kit, comprising a pergolide solution contained within a container configured to dispense a measured dosage of the pergolide solution and instructions for use.

Assignees

• Univ Oregon

Inventors

• Ambati Balamurali
• Kumar Sangeetha Ravi
• Trempy Kieley
• Zhang Xiaohui

Classifications

• A61K47/36

  Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin · CPC title

• A61K9/0048

  Eye, e.g. artificial tears · CPC title

• A61K47/38

  Cellulose; Derivatives thereof · CPC title

• A61P27/02

  Ophthalmic agents · CPC title

• A61K31/48 Primary

  Ergoline derivatives, e.g. lysergic acid, ergotamine · CPC title